OBJECTIVES: This study was designed to evaluate the efficacy and safety of reducing @entity205 ( @entity9472 ) dosing frequency from daily to every other day (EOD) or twice a week (TW) according to clinical response in @entity468 with @entity56 ( @entity56 ) and treated with @entity9472 . METHODS: One hundred and ninety-one @entity468 with @entity56 were given 7 mg/kg @entity9472 daily for at least 4 weeks. Depending on clinical response, the dosing frequency was tapered from daily to EOD over the next 4 weeks and further to TW for an additional 4 weeks. Safety was evaluated through physical examinations, clinical pathology and the monitoring of adverse events (AEs). RESULTS: The majority of @entity468 were able to have their dose of @entity9472 tapered to either EOD (15.5%) or TW (62.9%) according to the clinical response. Observed AEs were most frequently mild and self-limiting @entity391 and @entity294 . A higher percentage of AEs occurred with daily administration (73%) compared with other dosing regimens (27%). CONCLUSIONS AND RELEVANCE: Following 4 weeks of daily dosing at 7 mg/kg, @entity9472 may be tapered to EOD or TW while maintaining the desired therapeutic response in @entity468 with @entity56 . Additionally, @entity9472 appears to be well tolerated with fewer AEs at EOD or TW dosing. Establishing the lowest effective dosing frequency of @entity9472 improves the drug's safety profile.

Clinical efficacy and safety following dose tapering of @entity205 in XXXX with @entity56 .

@entity9472 :: ('D016572', 'Chemical') :: ['CsA', 'CSA'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['ciclosporin'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity dermatitis', 'HD'] @entity468 :: ('9685', 'Species') :: ['cats']
@entity468 :: (9685,Species) :: ['cats']
